EGFR and non-small cell lung carcinoma: In patients with advanced NSCLC treated with erlotinib, 18F-FDG PET presented a predictive effect as early as 1 week after initiation of treatment, predicting PFS, OS, and non-progression after 6 weeks of treatment, and was independent of EGFR mutational status (100).